Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura H Tang

Showing results (141-150 of 161) with videos related to

Pageof 17
Sort By:
The American Journal of Surgical Pathology|January 19, 2012
Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumorsShinichi Yachida, Efsevia Vakiani, Catherine M White, et al.
Journal of the National Cancer Institute|January 16, 2010
Verification and unmasking of widely used human esophageal adenocarcinoma cell linesJurjen J Boonstra, Ronald van Marion, David G Beer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2017
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinomaMaeve A Lowery, David P Kelsen, Marinela Capanu, et al.
Annals of Surgical Oncology|January 4, 2020
Correction to: Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric CancerElke J A H van Beek, Jonathan M Hernandez, Debra A Goldman, et al.
Annals of Surgical Oncology|May 5, 2018
Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric CancerElke J A H van Beek, Jonathan M Hernandez, Debra A Goldman, et al.
Annals of Surgery|June 6, 2014
A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinomaEileen M OʼReilly, Anna Perelshteyn, William R Jarnagin, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
Disrupted priming within draining lymph nodes drives immune quiescence in gastric cancerSohrab Salehi, Emily E Stroobant, Hannah Lees, et al.
The American Journal of Surgical Pathology|February 2, 2010
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data setDavid S Klimstra, Irvin R Modlin, N Volkan Adsay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2021
Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and PathwaysSmita Sihag, Samuel C Nussenzweig, Henry S Walch, et al.
Annals of Surgery|February 10, 2023
Durvalumab and PET-Directed Chemoradiation in Locally Advanced Esophageal Adenocarcinoma: A Phase Ib/II StudyDarren Cowzer, Abraham Jing-Ching Wu, Smita Sihag, et al.
Pageof 17

Showing results (141-150 of 161) with videos related to

Sort By:
Pageof 17
The American Journal of Surgical Pathology|January 19, 2012
Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumorsShinichi Yachida, Efsevia Vakiani, Catherine M White, et al.
Journal of the National Cancer Institute|January 16, 2010
Verification and unmasking of widely used human esophageal adenocarcinoma cell linesJurjen J Boonstra, Ronald van Marion, David G Beer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2017
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinomaMaeve A Lowery, David P Kelsen, Marinela Capanu, et al.
Annals of Surgical Oncology|January 4, 2020
Correction to: Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric CancerElke J A H van Beek, Jonathan M Hernandez, Debra A Goldman, et al.
Annals of Surgical Oncology|May 5, 2018
Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric CancerElke J A H van Beek, Jonathan M Hernandez, Debra A Goldman, et al.
Annals of Surgery|June 6, 2014
A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinomaEileen M OʼReilly, Anna Perelshteyn, William R Jarnagin, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
Disrupted priming within draining lymph nodes drives immune quiescence in gastric cancerSohrab Salehi, Emily E Stroobant, Hannah Lees, et al.
The American Journal of Surgical Pathology|February 2, 2010
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data setDavid S Klimstra, Irvin R Modlin, N Volkan Adsay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2021
Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and PathwaysSmita Sihag, Samuel C Nussenzweig, Henry S Walch, et al.
Annals of Surgery|February 10, 2023
Durvalumab and PET-Directed Chemoradiation in Locally Advanced Esophageal Adenocarcinoma: A Phase Ib/II StudyDarren Cowzer, Abraham Jing-Ching Wu, Smita Sihag, et al.
Pageof 17